The FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.| U.S. Food and Drug Administration
The Centers for Medicare & Medicaid Services (CMS) recently announced the drugs selected for the second round of negotiation for the Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and CMS's implementation of the program, with a focus on the details that apply for 2027, the second year that negotiated prices will be available under the program.| KFF
The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.| KFF
Prices for semaglutide and tirzepatide drugs are higher in the U.S. than in other countries. The U.S. has by far the highest rates of adults with obesity.| Peterson-KFF Health System Tracker